Pernix Therapeutics Holdings Inc
Pernix Therapeutics — Corporate Update (July 2017)
12 slides from Pernix Therapeutics's corporate update, Jul 20, 2017
Slide 1: Transaction Overview & Corporate Strategy Update July 2017
Transaction Overview & Corporate Strategy Update July 2017
Slide 2: Safe Harbor Statement
2 Safe Harbor Statement Triptans TRx (99%) This presentation includes forward - looking statements, including statements regarding the progress and timing of our product dev elopment programs and related trials; our future opportunities; our strategy, future operations, anticipated financial positio
Slide 3: Overview of Refinancing & Settlement Transactions
3 Overview of Refinancing & Settlement Transactions On July 20, 2017, Pernix Therapeutics Holdings, Inc. (“Pernix” or the “Company”) announced a series of transactions intended to improve liquidity, extend debt maturities and enable the Company to create value for all stakeholders New ABL Facility N
Slide 4: Pro Forma Debt, Liquidity and Share Count
4 Amount Oustanding (7/18/2017) Transaction Adjustments Pro Forma Amount Outstanding ABL Facilty $14 - $14 Treximet Notes 177 - 177 Delayed Draw Term Loan - 30 30 Total Secured Debt $191 $30 $221 Convertible Notes 130 (52) 78 Exchangeable Senior Notes - 36 36 Total Debt $321 $14 $335 Cash 20 22 42 N
Slide 5: Revised Debt Maturity & GSK Settlement Schedule
5 $7 $0 $0 $177 $78 $80 2017 2018 2019 2020 2021 2022 GSK Settlement Payments Treximet Notes Convertible Notes ABL Facility Delayed Draw Term Loan 4.25% / 5.25% Exchangable Senior Notes $15 $4 $17 $177 $130 $0 2017 2018 2019 2020 2021 2022 GSK Settlement Payments Treximet Notes Convertible Notes ABL
Slide 6: Corporate Strategy Overview
6 Drive Net Sales by Focusing on Core Strengths in Neurology and Pain Grow Profitability and Maximize Cash Flow Expand and Diversify Product Portfolio Corporate Strategy Overview Pernix Therapeutics is a patient centered, growth oriented specialty pharmaceutical company focused on developing, acquir
Slide 7: Business Development Focus
7 Business Development Focus Targeted business development effort focused on Neurology, Pain and adjacent indications Acquisitions, In - licenses and Co - promotes • Disciplined • Opportunistic Focus on Commercial Products or Products with Potential to Reach Market within 12 Months • De - Risked • A
Slide 8: Invest in Core Products to Reinvigorate Growth & Enhance Value
8 Invest in Core Products to Reinvigorate Growth & Enhance Value - Prepare for and Execute Successful Launch of Authorized Generic in Q1 2018 - Focus on high potential Pain Specialists - Highlight clinical differentiation and the unmet need in target market - Pursue options for adding abuse - deterr
Slide 9: Financial Goals & Priorities
9 $0 $10 $20 $30 $40 2016A 2017E 2020E Preliminary Target Range for Potential Business Development Current Business Financial Goals & Priorities Drive Adj. EBITDA to reach scale by 2020 through organic growth and business development activities Optimize Capital Structure opportunistically: Additiona
Slide 10: Pernix Therapeutics
_PERNIX. THERAPEUTICS Apeene
Slide 11: Non-GAAP Reconciliation: Adj. EBITDA
11 Non - GAAP Reconciliation: Adj. EBITDA ($ in millions) 1) Other Adjustments include change in fair value of contingent consideration, change in fair value of derivative, foreign curre ncy transaction (gain) loss, and restructuring costs. Note: 2020E Adjusted EBITDA is a non - GAAP financial measu
Slide 12: Non-GAAP Financial Measures
12 Non - GAAP Financial Measures To supplement our financial results determined by GAAP, we have also disclosed in this presentation and the table below the f oll owing non - GAAP information: adjusted earnings before interest, taxes, depreciation and amortization (EBITDA). Adjusted EBITDA is a non
Pernix Therapeutics Holdings — Corporate Update (July 2017) on 6ix